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Abstract 
Antioxidant plays an important role in preventing the progression of diabetes mellitus (DM) complications. This 
study was undertaken to evaluate the hypoglycemic effect of glutathione complex in Alloxan induced diabetic rats. 
Thirty albino rats (weighing 120-130g) were divided into six groups of five rats each: Group one serves as normal 
control, group two served as diabetic control while Group three, four and five were diabetic and administered with 
2.4mg/kg body weight, 3.6mg/kg body weight and 4.8mg/kg body weight respectively. All treatments were 
administered orally for 4 weeks on daily basis. Serum glucose level was measured at an interval of three days 
throughout the period of the experiment. Results obtained showed that administration of Glutathione Complex to 
diabetic rats caused a significant decrease (p<0.05) in serum glucose level compared to diabetic control. These 
results suggest that administration of Glutathione Complex to diabetic rats may help reverse the complications of 
diabetes mellitus. 
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1. Introduction 
The incidence of diabetes mellitus (DM) is prevalent over all parts of the world. It is also associated with reduced 
quality of life and increased mortality and morbidity factors. DM is a complex, progressive disease, which is 
accompanied by multiple complications. Diabetes mellitus is a multi-faceted metabolic disorder where there is 
increased oxidative stress that contributes to the pathogenesis of this debilitating disease. This has prompted 
several investigations into the use of antioxidants as a complementary therapeutic approach (mandrup-poulsen, 
1998). Data collected from clinical studies indicate that majority of the diabetic patients die due to cardiovascular 
diseases and atherosclerosis, which accounts for about 8 to 10% of all diabetic deaths. The established relationship 
between DM and atherosclerosis has fuelled suggestion to search for antidiabetic drugs with beneficial effects in 
reducing the atherosclerotic process in diabetic patients (Hokanson, 2002). Hyperglycemia is attributed to the 
development of diabetic complications. Hyperglycemia leads to increase in oxidative stress due to the 
overproduction of free radicals and decreased efficiency of antioxidant defense system. It occurs particularly in 
patients with poor glycemic control (Wiernsperger, 2003). Oxidation of lipids, proteins and other macromolecules 
(such as DNA) occurs during the development of diabetes and its complication. To control the influx of free 
radicals, aerobic cells have developed an antioxidant defense system, which directly or indirectly scavenges free 
radicals or prevents their conversion to toxic products (IDF, 2013). The stability and capacity of antioxidant status 
during chronic diabetes seriously influences the outcome of the long-term complications caused by oxidative stress. 
In 2004 the makers of glutathione complex embarked on a business plan to develop the company's most 
powerful product for supporting good immune function (and also skin lightening). Not only was this formula 
meant to be effective, but also safe for normal use. Though the idea was simple enough, the research and 
development to create such product was surprisingly extensive. Every possible factor was considered in creating 
this revolutionary proprietary formula. This Essentials Blend 1500mg contains: Glutathione, Alpha Lipoic Acid, 
Milk Thistle, L-Cysteine, Other ingredients: Hypermellose, Cellulose and Magnesium Stearate. After two years 
of tests and trials, it was finally available for the public in the fall of 2006. Since then, the R&D Team has been 
continuously improving the formula and product line with new innovations making this glutathione complex the 
most advanced formula on the market today (Dermazone, 2014). 
The ingredient in the Complex “Essential Glutathione Complex" has been clinically tested to provide 
maximum benefit. Glutathione complex restores the function of organs particularly the liver. This complex 
improves the overall health and well-being of the body. It boosts the energy level as it contains α-lipoic acid in 
addition to high concentration of glutathione. Glutathione flushes the toxins that build up in the liver.  
There were postulations that glutathione complex can also serves as anti-hyperglycemic agent and therefore 
alleviating the complications of diabetes mellitus. This research work aims at investigating the anti-hyperglycemic 
potentials of glutathione complex (gluatathione, L-cystein, α-lipoic acid and milk thistle) using alloxan induced 
diabetic rats.  
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2. Materials and Methods 
2.1. Experimental Animals 
Thirty (30) albino rats (weighting 120 to 130g) were purchased from the department of biological science, Bayero 
University Kano and they were housed in colony cages at an ambient temperature and relative humidity. The 
animals had free access to standard palletized grower feed and drinking water and the experiments was performed 
according to the principles of laboratory animal care. 
 
2.2. Sample Collection and Preparation  
Glutathione complex was purchased from Hasiya Bayero Hospital, Kano. 1500mg of the complex was dissolve in 
100ml with water. The volume administered was calculated according to the relation. 
 
Volume to be administered (cm3)   =    weight of rat (kg)      dose in mg/kg (50mg/kg) 
                                                                   Concentration of Alloxan Solution (mg/ml) 
 
2.3. Induction of Diabetes  
A stoke solution of Alloxan was prepared by dissolving 1g of the Alloxan in 100ml of water (100mg/ml). After 8-
hours of fasting, the rats were weighed, Lying on its back, the animals were given single intraperitoneal injection 
of alloxan. The volume of Alloxan administered was determined by the weight of the rat according to the following 
relationship. 
 
Volume to be administered (cm3)   =    weight of rat (kg)      dose in mg/kg (50mg/kg) 
                                                              Concentration of Alloxan Solution (mg/ml)  
 
In order to assess the effect of alloxan and to chemically establish the diabetic condition, an incision was done in 
any of the four veins in the tail of the rats using a blade after 48hrs of induction. A sample of the rat venous blood 
was collected on a reagent strip for blood glucose level determination using a portable glucose analyzer. The level 
of serum glucose considered to be normal in rattus novergicus ranges from 50 to 135 mg/dl. In this study, rats with 
glucose levels above 200mg/dl were considered as having severe diabetes. 
 
2.4. Experimental Design  
A total of 30 rats were divided into six groups of five rats per group as follows;  
Group I: Normal Control 
Group II: Diabetic control 
Group III: Diabetic rats, administered with 2.4mg/kg of glutathione complex 
Group IV: Diabetic rats, administered with 3.6mg/kg of glutathione complex 
Group V: Diabetic rats, administered with 4.8 mg/kg of glutathione complex  
Group VI: Diabetic rats, administered with 7.8 mg/kg of glutathione complex 
The blood glucose level of all the rats was measured (from the tail) prior to induction of diabetes using alloxan. 
After 48 hours of induction, the blood glucose level of group II to VI was checked to confirm induction. The blood 
glucose level of all the groups was measured after every two days for a period of four weeks. 
 
3. Results 
From the animals subjected to diabetes induction, 73% developed severe diabetes mellitus; 20% developed mild 
condition; and the remaining 7% died within the first week of follow up, probably due to acidosis. The animals 
showed the following signs of the condition: polydipsia (abnormal thirst), polyuria (increased urine volume), 
weight loss (due to lean mass loss), asthenia (weakness due to the inability to use glucose as a source of energy), 
dehydration (due to the animal’s body attempt to get rid of the excess blood glucose as the normal process of 
storing glucose in the body cells is impaired). 
Table1 present Fasting Blood Glucose Level (mg/dl) in alloxan induced diabetic rats before administration 
of Glutathione Complex, and at intervals of three days after oral administration of Glutathione Complex for four 
weeks. Blood glucose level of positive control was significantly higher than that of negative controls (p<0.05) 
48hrs after induction of diabetes. Four weeks after administration with Glutathione Complex, rats in groups III, 
IV, V and VI were found to have lower blood glucose level than groups II. The observed difference between the 
groups were significant (P<0.05).  
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Table 1: Fasting Blood Glucose Level (mg/dl) in Alloxan Induced Diabetic Rats Administered with Glutathione 
Complex for four weeks 
 GI GII GIII GIV GV GVI 
NoAlx 85±1.51 85± 2.51a 83±2.60a 84±1.09a 83±2.44a 86±2.68a 
Alx,48 85±2.19 330±22.36abcdefghi 183±3.96abcef 214±17.53abcdef 285±14.17abcde 287±22.32abcdefg 
Day3 86±2.19 329±21.35b 177±3.67 200±17.01 268±14.17 299±22.32 
Day6 85±1.09 328±24.82c 168±3.49 187±15.28 250±13.51 276±21.38 
Day9 87±2.19 328±23.15d 157±2.88 174±14.77 232±13.38 253±19.64 
Day12 83±2.60 326±23.02e 146±2.30 160±13.95a 214±12.58 228±18.75b 
Day15 86±2.49 327±23.45f 135±2.49b 145±13.80b 195±12.74a 204±18.91c 
Day18 86±1.79 325±23.35g 126±1.96c 130±13.52c 176±12.63b 183±19.13d 
Day21 84±1.09 324±22.05h 114±2.88d 116±13.24d 157±12.54c 165±19.11e 
Day24 84±1.95 323±20.66i 104±2.70e   102±11.45e 139±12.01d 146±17.95f 
Day27 84±1.34 323±20.66j 92±2.58f 91±7.36f 120±11.91e 129±16.59g 
Values are mean ± Standard deviations. Values bearing same superscripts across the groups differ significantly 
(P˂0.05). Key: ALX= Alloxan, GI=Group One, GII=Group two, GIII=Group Three, GIV=Group Four, 
GV=Group Five, GVI=Group Six. 
 
4. Discussion 
Alloxan-induced diabetic rat is one of the animal models of human diabetes mellitus. Diabetes arises from 
irreversible destruction of pancreatic β-cells, causing degranulation and reduction of insulin secretion (Zhang and 
Tan, 2000). Alloxan induced diabetes is characterized by hyperglycemia and a severe loss in body weight (Chen 
and Ianuzzo,1982) and may exhibit most of the diabetic complications such as, myocardial, cardiovascular, 
gastrointestinal, nervous, kidney and urinary bladder dysfunction through oxidative stress (Rajasekaran et al., 
2005). The decrease in body weight in diabetic rats shows that the loss or degradation of structural proteins is due 
to diabetes, and structural proteins are known to contribute to the body weight (Rajkumar and Govindarajulu, 
1991). In diabetes mellitus, there is oxidative stress associated with release of free radicals.  Increased oxidative 
stress in diabetes is also considered as a contributing factor in the development of diabetic complications, including 
nephropathy, retinopathy (Haskins et al., 2003), and reactive oxygen species generated by high glucose act as a 
causal link between elevated glucose and the other metabolic abnormalities important in the development of 
diabetic complications (Brownlee, 2001).  
In the present study, blood glucose level in alloxan induced diabetic rats was significantly higher as compared 
to the normal control rats which may be due to destruction of the β-cell of pancreas and lead to reduction of insulin 
secretion, thereby leading to increase in plasma glucose levels and a severe loss of body weight. This finding 
agrees with the report of Oyedemi et al. (2011), who observed similar effect on diabetic animals treated with 
streptozotocin (STZ). Therefore, the reduction in body weights may be linked to degradation of structural proteins 
and increased muscle wasting due to loss of tissue proteins (Daye et al., 2013).  Glutathione (GSH), a tripeptide 
present in all the cells is an important antioxidant. A decreased glutathione level in diabetes has been considered 
to be an indicator of increased oxidative stress (Lu, 1999). GSH also functions as free radical scavenger and in the 
repair of radical caused biological damage. A decrease was observed in GSH in liver and kidney during diabetes. 
The decrease in GSH level represents increased utilization due to oxidative stress (Anuradha and Selvam, 1993). 
Administration of Glutathione Complex for four weeks shows some anti-hyperglycemic effect (hypoglycemic 
effects) in alloxan-induced diabetic rats. When diabetic rats were administered with Glutathione Complex, the 
weight loss was recovered. The capability of Glutathione Complex to reduce hyperglycemia and protect body 
weight loss seems to be related to its alpha lipoic acid (ALA), L-cysteine and glutathione (in addition to milk 
thistle, green tea etc) contents. These compounds may be responsible for it antidiabetic and antioxidant activity, 
which attributed to its protective action on lipid peroxidation and to the enhancing effect on cellular antioxidant 
defense contributing to the protection against oxidative damage in alloxanized diabetes. The present finding 
corroborates the report of Samar et al (2010), who showed that supplementation of ALA significantly reduced 
STZ induced hyperglycemia in animals with a significant improvement on the body weights of diabetic animals 
when compared with the control group, which indicated that ALA prevented muscle tissue damage due to diabetic 
condition. The anti-diabetic activity of ALA has been reported to be due its ability to regulate glucose metabolism 
(Singh and Jialal, 2008). In addition, Khamaisi et al., (1997) showed that ALA administration to diabetic animals 
reduced blood glucose concentration by enhancing muscle GLUT4 protein content and thus increased muscle 
glucose utilization. This present finding was further substantiated by the findings of Vessal et al (2003) who 
reported that Alpha Lipoic Acid (ALA) serves beneficial effects in decreasing blood glucose concentration, 
promoting regeneration of the pancreatic islets and increasing insulin release in STZ-diabetic rats. ALA is a potent 
antioxidant that has effects on fuel metabolism and also acts as an essential cofactor of mitochondrial respiratory 
Advances in Life Science and Technology                                                                                                 www.iiste.org 




enzymes, including the pyruvate dehydrogenase (PDH) complex (Nagamatsu et al., 1995).  Several studies suggest 
alpha-lipoic acid helps lower blood sugar levels. Its ability to kill free radicals may help people with diabetic 
peripheral neuropathy, who have pain, burning, itching, tingling, and numbness in arms and legs from nerve 
damage (Ibrahimpasic, 2013). Researchers believe Alpha-lipoic acid helps improve insulin sensitivity. Taking 
alpha-lipoic acid may help another diabetes-related condition called autonomic neuropathy, which affects the 
nerves to internal organs (Mitkov et al., 2013). Alpha-lipoic acid has been used for years to treat peripheral 
neuropathy in Germany. One study of 73 people with cardiac autonomic neuropathy, which affects the heart, found 




In conclusion, the current study shows that administration of glutathione complex resulted in a significant 
hypoglycemic effect during the alterations of impaired blood glucose level and antioxidant status in diabetic 
condition. Thus, the complex can be recommended for the management of diabetes mellitus. 
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